Kura Oncology (KURA) Non-Current Debt (2014 - 2026)

Kura Oncology (KURA) has 12 years of Non-Current Debt data on file, last reported at $9.7 million in Q1 2026.

• Non-Current Debt for Q1 2026 came in at $9.7 million, up 27.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.7 million (up 27.44% YoY), and the FY2025 annual result was $9.7 million, up 40.41% from the prior year.
• Non-Current Debt was little changed at $9.7 million in Q1 2026 per KURA's latest filing, from $9.7 million in the prior quarter.
• Over five years, Non-Current Debt peaked at $9.7 million in Q1 2026 and troughed at $5.3 million in Q3 2025.
• A 5-year average of $8.4 million and a median of $9.2 million in 2022 frame the typical range for Non-Current Debt.
• On a YoY basis, Non-Current Debt climbed as much as 40.41% in 2025 and fell as far as 31.21% in 2025.
• A 5-year view of Non-Current Debt shows it stood at $9.2 million in 2022, then rose by 1.9% to $9.3 million in 2023, then fell by 25.89% to $6.9 million in 2024, then jumped by 40.41% to $9.7 million in 2025, then rose by 0.39% to $9.7 million in 2026.
• Business Quant data shows KURA's Non-Current Debt at $9.7 million in Q1 2026, $9.7 million in Q4 2025, and $5.3 million in Q3 2025.